MESOMESOBLAST LTD

Nasdaq mesoblast.com


$ 6.14 $ 0.04 (0.66 %)    

Monday, 09-Sep-2024 15:50:50 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 6.14
$ 6.13 x 100
-- x --
-- - --
$ 1.61 - $ 12.64
34,457
na
1.4B
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jefferies-upgrades-mesoblast-to-buy

Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.

 cantor-fitzgerald-reiterates-overweight-on-mesoblast

Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.

 piper-sandler-upgrades-mesoblast-to-overweight-raises-price-target-to-11

Piper Sandler analyst Edward Tenthoff upgrades Mesoblast (NASDAQ:MESO) from Neutral to Overweight and raises the price targe...

 reported-earlier-mesoblast-resubmits-biologics-license-application-bla-for-ryoncil-to-fda-targeting-treatment-for-children-with-sr-agvhd

FDA granted remestemcel-L Fast Track designation, a process to facilitate the development and expedited review of therapies for...

 why-nio-shares-are-trading-lower-by-over-8-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has res...

 mesoblast-to-submit-fda-application-for-ryoncil-in-treating-pediatric-gvhd

Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today co...

 cantor-fitzgerald-reiterates-overweight-on-mesoblast

Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-mesoblast

Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION